This site is intended for healthcare professionals residing in Canada.
Menu
Close
Menu
Close
Recommendations
SOGC Recommendations
NACI Recommendations
CIQ Recommendations
About RSV
About RSV
Infants at Risk
Individuals ≥ 60 Years of Age
About ABRYSVO
Reconstitution and Storage
Dosing and Administration
Mechanism of Action
Efficacy and Safety Profiles
Clinical Trials
MATISSE Study Design
MATISSE Data
MATISSE Safety Profile
RENOIR Study Design
RENOIR Data
RENOIR Safety Profile
More
Coverage Information
Patient Profiles
FAQ
Resources
A bivalent formulation containing two recombinant stabilized RSV prefusion F antigens, each representing the two major virus subgroups (RSV A and RSV B).
Following intramuscular injection, prefusion F antigens elicit an immune response, which helps protect against RSV-associated LRTD.
In pregnant individuals
Action of neutralizing antibodies conferring protection is mediated by passive transfer of these antibodies from mother to infant.
In individuals ≥ 60 years of age
Protection via active immunization.
RSV: respiratory syncytial virus; LRTD: lower respiratory tract disease
*Comparative clinical significance has not been established.
Learn more about respiratory syncytial virus and its impact on high-risk populations.
Investigate ABRYSVO’s efficacy and safety profiles in infants and individuals ≥ 60 years of age.
To report an adverse event, please call 1-866-723-7111
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.